We're on a mission to revolutionize women's health care.
We aspire to significantly enhance the quality of life and care of women by empowering patients and health care professionals with intelligent drug delivery and diagnostics. We are developing a unique platform in the field of smart therapies with a market launch planned in 2024 that has the potential to transform the way women are treated, monitored, and diagnosed.
How unique it is to be able to personally adjust the administration of medicine in the MedRing as a woman!!
Marlies Bongers, Prof. MD PhD
It is refreshing to see novel initiatives such as the MedRing, which offers a potential paradigm shift for drug delivery and diagnostics. I expect its clinical applications will transform the treatment of women’s health.
Karolina Afors, MBBS BSc MRCOG
Having known Willem de Laat and Maarten Wiegerinck for more than 40 years, it is a privilege to endorse LiGalli. I did a lot of fertility work with them, and I am proud to be a small part of LiGalli in the future. It is impressive to see how far LiGalli has come from where it started!
I have followed the development of LiGalli and the revolutionary vaginal ring, and I am extremely impressed with this innovation. This ring encapsulates the essence of modern technology, finding a solution that seamlessly fits into today’s society and empowers women.
The MedRing’s modern, personalized approach to women’s health has the potential to dramatically shift the health of people around the world. By letting people manage their treatment in the palm of their hand, the MedRing enables people to have more power over their health and health outcomes.
Amanda Srsic, MPH
Meet the leadership team
Willem de Laat
Director Pre-Clinical & Pharma
Director Clinical & Sensoring
Thijs van Oorschot
Director Technology & IT
Director Business Development
per June 1, 2021
Barry van Amsterdam
Director Business Valuation
Why we care
women are underrepresented
- Women’s health has been underrepresented in medical investment, research, and innovation.
- Medical solutions for women have not yet been fully explored because a male-first approach has been adopted.
We prioritize the wellbeing of women and offer personalized treatment.
existing solutions are challenging
- Millions of women experience problems, side effects, and intolerability related to the current treatments.
- Women are 50-75% more likely to have adverse reaction to medications than men.
The vaginal wall facilitates rapid uptake of drugs and avoids the major side effects associated with swallowing a pill.
technology is outdated
- The lack of innovation in women’s health has led to current solutions that do not adequately support women.
- This stagnation is leading to poorer quality of life and lower health outcomes.
The MedRing combines intelligent drug delivery and diagnostics to advance women’s health.
Life is complicated.
Your health care
Meet the supervisory board
Cees van den Heijkant
CHAIRMAN OF THE BOARD
Cees is a mature and senior businessman and entrepreneur as well as professional investor. Cees successfully invests in IT/tech companies, sometimes jointly with PE funds, as well as in start-ups with disruptive character.
Godert is a keen businessman and professional investor. He was involved in the setup of LiGalli from the early beginnings. His expertise lies in telecom and data management but also in corporate finance.
Carl is Managing Partner at Eagle Rock LS. Carl developed his deep understanding of the pharmaceutical industry through various marketing and sales positions in leading corporations. His current consultancy business has only added more weight to his expertise.
We partner with the best and
most creative minds.
Our successful and diverse partnerships have leveraged ambition, innovation, and results.
Prof. Douwe D. Breimer
LEIDEN UNIVERSITY, NL
PhD, Em Professor of Pharmacology
Prof. Bart CJM Fauser
UNIVERSITY OF UTRECHT, NL
MD, PhD, FRCOG, Em Professor of Reproductive Medicine
Dr. Nel Duijvestijn
MCH HOSPITAL, THE HAGUE, NL
Endocrinologist and expert in diabetes and glucose sensoring
Prof. Jeffrey T. Jensen
OREGON HEALTH AND SCIENCE UNIVERSITY PORTLAND, OREGON USA
MD, MPH, Depts Obs & Gynecol and Public Health and Preventive Medicine
EX-CEO ORGANON PHARMACEUTICALS
Responsible for first innovative vaginal ring world wide (Nuvaring®). “That was a first generation ring, this one opens exponentially more possibilities.”
Cees van Lede
“ The LiGalli MedRing 2.0 makes me smile. It is a contemporary innovation of Organon’s first worldwide vaginal ring in the past”
Prof. Karl Malcolm
QUEEN’S UNIVERSITY OF BELFAST, N. IRE
Professor of Drug Delivery at School of Pharmacy expert in vaginal rings and animal studies
Prof. H. van der Vaart
UNIVERSITY MEDICAL CENTER UTRECHT, NL
Urogynecologist and expert in overactive bladder
Interested in collaborating?
We are looking for partners as we move our business to the market. Reach out below if you’d like to work together.